ABSTRACT PURPOSE: To investigate whether dilute brimonidine (0.025%) reduces patient discomfort, subconjunctival hemorrhage, and injection after LASIK without a significant increase in the rate of fl ap complications or surgical enhancements.
RESULTS: Scores of patient discomfort, subconjunctival hemorrhage, and injection were signifi cantly lower in eyes treated with dilute brimonidine at the 1 hour and 1 day postoperative examinations. Refl oats for mildfl ap edge wrinkling were required in 3 brimonidine eyes (2.5%), 1 naphazoline/pheniramine eye (0.8%), and no control eyes, but this difference did not reach statistical signifi cance (P = .18). There was no signifi cant difference between eyes at 3 months in terms of visual acuity, refractive error, corrected distance visual acuity, or rate of enhancement.
CONCLUSIONS:
Use of dilute brimonidine before LASIK reduces subconjunctival hemorrhage and injection and improves patient comfort after surgery. Flap edge wrinkling requiring refl oat may still be a complication with dilute brimonidine.
[J Refract Surg. 2013;29(7): 469-475.] ne of the reasons that LASIK has become the dominant refractive procedure is that it involves significantly less postoperative patient discomfort than other keratorefractive procedures. 1 Efforts have been made to improve comfort further, but they have not gained widespread adoption. 2, 3 In our experience, one means of improving early postoperative patient comfort is the use of a single drop of dilute brimonidine (0.025%) prior to surgery.
Use of brimonidine before lamellar procedures has been studied for the reduction of subconjunctival hemorrhages that frequently occur due to the suction required for corneal applanation. 4 Although these hemorrhages are temporary and without signifi cant visual consequence, reducing or eliminating them provides a more positive patient experience, avoids undue negative psychological effects, and enhances aesthetic outcomes in the procedure with a signifi cant cosmetic component. Topical vasoconstrictors such as brimonidine, [5] [6] [7] [8] apraclonidine, 9 phenylephrine, 10 or combined naphazoline/pheniramine eye drops 11 help reduce postoperative subconjunctival hemorrhage, injection, and hyperemia. However, the use of these medications has been avoided due to the possibility that they may increase the incidence of fl ap dislocations 8 and the frequency of surgical enhancements. 5 It remains controversial whether brimonidine increases the rate of fl ap dislocation; of two recent prospective contralateral eye studies investigating the use of brimonidine 0.2% before LASIK, one demonstrated no increase in fl ap dislocation and the other demonstrated a 10.4% increase in the rate of fl ap dislocation. 6, 8 Another concern with the use of these medications is their effect on pupil size and shape, [12] [13] [14] which could potentially interfere with pupil tracking.
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In designing this study, we hypothesized that an optimal dilution of brimonidine could reduce the rate of complications associated with full dose brimonidine while maintaining the benefi ts. We present a prospective, randomized, double-blind study comparing 0.025% brimonidine, naphazoline/pheniramine, and control (artifi cial tears lubricant) to determine whether subconjunctival hemorrhage and injection can be minimized effectively without increasing the risks of fl ap dislocation or need for enhancement. In addition, we evaluated the validity of our observation that dilute brimonidine is effective in reducing patient discomfort in the fi rst 24 hours after surgery, a fi nding that has not been previously reported.
PATIENTS AND METHODS
This prospective, randomized, double-blind, singlecenter clinical trial evaluated 180 patients (360 eyes) undergoing bilateral LASIK for refractive errors ranging from +6.00 to -12.00 diopters (D) sphere and up to -6.0 D of astigmatism. Inclusion criteria were a stable refraction for 1 year, an average central corneal thickness of at least 500 μm, and an otherwise healthy anterior segment. Written informed consent was obtained for all patients and the study was approved by an RCRC Independent Review Board.
Eligible patients were examined preoperatively for measurement of corrected and uncorrected distance and near vision, cycloplegic and manifest refraction, pachymetry, corneal topography, and slit-lamp and fundus examinations. Pupil diameter was measured under mesopic conditions using an infrared pupillometer (Neuroptics, Irvine, CA) during the preoperative visit. Postoperatively, patients underwent an ophthalmic evaluation at 1 hour, 1 day, 1 month, and 3 months. All eyes were assessed according to standard criteria for satisfactory LASIK outcomes related to safety, predictability, and effi cacy. Each patient was asked to complete a subjective questionnaire 1 hour and 1 day postoperatively for self-evaluation of discomfort, irritation, burning, pain, and itching on a scale of 0 (none) to 7 (severe). Subconjunctival hemorrhage and injection were evaluated by slit lamp at 1 hour and 1 day postoperatively by a masked investigator using a grading scale of 0 (none) to 4 (severe) for each fi nding. Routine refraction and slit-lamp examinations were performed at the later postoperative visits.
Brimonidine tartrate ophthalmic solution 0.1% was compounded to 0.025% by an independent pharmacy in Overland Park, Kansas. Naphcon A (naphazoline hydrochloride 0.025%, pheniramine maleate 0.3%; Alcon Laboratories, Inc., Fort Worth, TX) and control (Systane Ultra, polyethylene glycol 400 0.4%, propylene glycol 0.3%; Alcon Laboratories, Inc.) are over-the-counter medications. All patients underwent bilateral surgery and were randomized to one of three regimens with 60 patients and 120 eyes each: (1) dilute brimonidine in one eye and control in the other eye, (2) naphazoline/pheniramine in one eye and control in the other eye, and (3) dilute brimonidine in one eye and naphazoline/pheniramine in the other eye. Five minutes prior to surgery, patients received one drop of the study medication according to the randomized group determination in addition to one drop of proparacaine and one drop of antibiotic.
A fourth-generation IntraLase FS Laser (60 kHz; Abbott Medical Optics, Santa Ana, CA) was used to create the LASIK fl aps. Flap diameter was 8.5 mm and the intended fl ap thickness was 110 μm. A raster pattern was used with the hinge located in the superior position with raster energy of 1.2 mJ/spot and spotline separation of 9 ϫ 9 μm. The hinge angle was 50° and the side cut angle was 70° with pocket software enabled. Pupil size was measured under standardized light levels using the infrared pupillometer in the interim between fl ap creation and excimer ablation. All patients underwent vision correction performed with the same excimer laser (Allegretto Wave Eye-Q; WaveLight AG, Erlangen, Germany). All eyes received proparacaine 0.5% and tetracaine 0.5% drops during surgery. The goal of surgery was emmetropia or monovision of -0.75 to -1.50 depending on patient age and surgeon discretion.
Immediately after surgery, patients received a fourth generation fl uoroquinolone antibiotic, prednisolone acetate 1%, and preservative-free artifi cial tears. Patients continued to use the antibiotic and steroid drops four times daily for 1 week and were encouraged to use the artifi cial tears frequently (every 15 to 30 minutes on the day of surgery, every 1 to 2 hours the day after surgery, tapering to six times daily with more frequent use if needed). Refl oats were performed in a procedure room with sterile technique and a microscope with the patient in supine position. Determination of need for enhancement was made at the 3-month postoperative visit at the surgeon's discretion based on uncorrected vision and magnitude of refractive error. A data analysis software package (SAS, Cary, NC) was used to evaluate statistical signifi cance. Results were analyzed by analysis of variance (ANOVA) with a Bonferroni correction test (alpha < .05, where alpha is a P value modifi ed for multiple variable correction). The three treatment groups were also compared two by two (pairwise) to generate P values using the two-sample t test and P values were checked against the Bonferroni grouping to confi rm agreement. Fisher exact test was used to calculate P val-Dilute Brimonidine for LASIK Patients/Pasquali et al ues for fl ap dislocation rates (a categorical comparison). Using the reported rate of 1% 15, 16 for the occurrence of fl ap dislocation in LASIK with femtosecond laser, power analysis determined that this study had 80% power to detect an increase of 0.06 (6%) in the rate of dislocation (GraphPad StatMate, San Diego, CA). Data are presented as mean ± standard deviation. P values less than .05 were considered signifi cant. 15, 16 Refractive outcome measures were calculated according to the standardized graphs as originally defi ned by Waring. 17 
RESULTS
The study included 360 eyes from 180 patients. There were no statistically signifi cant differences between the groups in terms of preoperative characteristics ( Table 1) . One hundred sixty-two patients (90%) completed 3 months of follow-up examinations. All patients completed at least 1 day of follow-up, which was suffi cient for inclusion in the analysis of fl ap dislocation, slit-lamp parameters (subconjunctival hemorrhage and injection), and patient questionnaires. However, only patients with 3 months of follow-up were able to be included in the analysis of visual outcomes and frequency of enhancements.
At 3 months, there were no signifi cant differences between eyes in the percentage achieving 20/20 (logMAR 0.00) or better uncorrected visual acuity (for the respective target distance), mean spherical equivalent, mean absolute error, corrected distance visual acuity (CDVA), or in the enhancement rate ( Table 2) . Mean absolute error is calculated as the absolute value of the difference between the postoperative manifest refraction (spherical equivalent) and the target refraction. Refractive outcomes for each group are reported in Figure 1 .
The use of dilute brimonidine or naphazoline/pheniramine signifi cantly reduced the amount of injection and subconjunctival hemorrhage 1 hour postoperatively when compared to control (Figure 2) , with dilute brimonidine demonstrating a greater amount of reduction than naphazoline/pheniramine (P р .006 for all pairwise comparisons for both parameters). In terms of incidence, only 10% of dilute brimonidine eyes were graded as having greater than "trace" subconjunctival hemorrhage versus 24% of the naphazoline/pheniramine eyes and 93% of control eyes. At the 1-day followup visit, dilute brimonidine and naphazoline/pheniramine continued to show a marked benefi t in reducing subconjunctival hemorrhage when compared to control (P < .001 for both comparisons) (Figure 2) , with dilute brimonidine exhibiting lower scores than naphazoline/ pheniramine (0.17 ± 0.43 vs 0.34 ± .016, P =.01). However, by the 1-day follow-up visit, injection scores were no different between treatment groups (ANOVA P = .32 with P у .16 for all pairwise comparisons).
According to questionnaire responses, patients who received dilute brimonidine or naphazoline/pheniramine were markedly more comfortable and less symptomatic than those who received control 1 hour postoperatively in terms of discomfort, irritation, burning, pain, and itching scores (P < .01 for all symptom score comparisons), whereas scores for dilute brimonidine and naphazoline/pheniramine were not statistically different Dilute Brimonidine for LASIK Patients/Pasquali et al Dilute Brimonidine for LASIK Patients/Pasquali et al (P > .23 for all symptom score comparisons). One day postoperatively, symptom scores for discomfort, burning, pain, and itching ( Figure 3) were statistically similar for the three treatment groups (ANOVA P > .09 for these four symptoms). Irritation scores 1 day postoperatively for eyes treated with control were signifi cantly higher when compared to scores for dilute brimonidine eyes (P = .047) and naphazoline/pheniramine eyes (P = .01); however, there was no difference between dilute brimonidine and naphazoline/pheniramine treatments (P = .63). Mild-fl ap edge wrinkling occurred in three (2.5%) of the dilute brimonidine eyes and one (0.8%) of the naphazoline/pheniramine eyes with no instances (0%) in the control group. This difference did not reach statistical signifi cance (P = .18, Fisher exact test). Two eyes were refl oated at 1 day and two eyes at 1 hour. No eyes experienced fl ap dislocations.
The 3-month outcomes for the four eyes requiring refl oat due to fl ap wrinkling are presented in Table 3 . All four eyes had 20/25 or better visual acuity and all corrected eyes had 20/20 or better visual acuity at their last follow-up visit with no loss of CDVA. None of the eyes demonstrated more than 0.50 D difference in sphere or cylinder between the target and achieved refractive outcome. One additional refl oat was performed 5 days postoperatively due to diffuse lamellar keratitis in a naphazoline/pheniramine group eye. The diffuse lamellar keratitis was likely related to an epithelial defect that developed after surgery unrelated to the study medication. The refl oat was not included in the analysis because it was not related to fl ap dislocation or wrinkling.
There were no instances of pupil size adversely affecting the ability of the laser software to accurately track pupil locations during the treatment in any of the eyes.
DISCUSSION
It is believed that brimonidine can destabilize fl ap adherence by adversely affecting corneal reepithe- Dilute Brimonidine for LASIK Patients/Pasquali et al lialization and endothelial cell function (the latter disrupting the negative intrastromal corneal pressure gradient responsible for early fl ap adherence). 18 Some studies have found no increase in the risk of fl ap complications with use of brimonidine, 6, 7 whereas other studies have reported an incidence of fl ap dislocation varying from 10% to 36%. 5, 8 We did not encounter any frank fl ap dislocations in 120 eyes treated with dilute brimonidine. There was a small trend toward fl ap wrinkling in these eyes, although this did not meet statistical signifi cance. Our study had power to detect a 6% difference. To detect a 1.5% or smaller difference in the rate of fl ap dislocation (baseline rate of 1% to 2% 15,16 versus 2.5% among brimonidine eyes in this study), a sample size of 2,000 or more eyes would be required. Enlarging our study to meet this number was not feasible.
Flap dislocation is a concern because of longterm visual consequences if not addressed appropriately; however, with prompt management these consequences are greatly mitigated. In a study using full dose brimonidine, the seven eyes that required refl oats for fl ap dislocation did not experience any further complications such as fl ap striae, epithelial ingrowth, or irregular astigmatism as of 6 months postoperatively. 8 We experienced no further complications after performing refl oats in the four eyes in our study with fl ap edge wrinkles and these eyes showed excellent visual outcomes and no loss of lines of CDVA.
Even though refl oating the fl ap was uncomplicated and those eyes requiring refl oats went on to have excellent outcomes, the signifi cance of refl oats should not be minimized. Refl oats are an additional procedure, requiring extra time for healing and follow-up, and may produce anxiety and discomfort. These potential consequences are important to consider given that we are seeking to increase patient comfort and minimize the social and psychological impact of subconjunctival hemorrhage. Even a potential and small increase (1.5%) in the rate of refl oats may still be too great for some surgeons.
Against this small, potential risk, we found significant benefi ts to using brimonidine. In particular, we measured decreases in patient reported levels of discomfort, irritation, burning, pain, and itching, with symptom scores among control eyes nearly double those of the medicated eyes 1 hour after surgery. Previous studies 6, 7 have focused on the reduction in subconjunctival hemorrhage but have not recognized this benefi t for patients. Our study is also different from previous studies in that only a fraction of the brimonidine dose (1/8) was required for the same dramatic reduction in the rate (93% vs 10%) and severity (average score of 1.6 vs 0.2) of subconjunctival hemorrhage (control vs brimonidine, respectively). Many surgeons believe that subconjunctival hemorrhage is of little or no importance given that it is self-limited and has no effect on visual outcomes. Still, patients may perceive a subconjunctival hemorrhage as a stark red sign that "something went wrong," as a bad outcome, or as an impediment to returning to normal social life or work. 4 Concern about these factors and about the overall patient experience is important for an elective procedure that depends on a positive patient experience.
We found general equivalency between groups in refractive outcomes at 3 months as demonstrated in the standard graphs for reporting refractive outcomes (Figure 1) . Although 3 months is a short period for evaluation of refractive outcomes, the main questions in our study regarded early differences in patient comfort and cosmesis. Visual outcomes were closely monitored to ensure that there were no major refractive differences between the drops early after surgery that might indicate an unforeseen risk or benefi t, with the likelihood that any major refractive difference resulting from a single drop of medication at the time of surgery would manifest by 3 months.
As part of this analysis, we found no differences between groups in frequency of enhancement. The possibility of increased rates of enhancement in eyes treated with brimonidine was fi rst observed in a small retrospective study, which, as the authors of that study point out, was meant merely to report observations and prompt further studies to the signifi cance of the observations. 5 In the studies that followed, no randomized prospective evidence was found to suggest that brimonidine increased the enhancement rate at all. [6] [7] [8] We believe that a 3-month follow-up period is not suffi cient for evaluating enhancement rate when regression can occur over longer time periods. We reason that one drop of a dilute medication used once before surgery is unlikely to have an effect on healing after 3 months, so if there were a dichotomy between the groups it is likely we would have observed it by that time. In addition, none of the eyes with mild fl ap edge wrinkling required enhancements, so if refl oats predispose eyes to needing enhancement the rate of this predisposition is small and was not detectable in our study.
Surgeons carefully weigh the risks of fl ap complications against the benefi ts of using brimonidine. We believe these are not mutually exclusive: by reducing the strength of brimonidine, the same level of benefi t can be garnered at a fraction of-and possibly even without-the risk. Our study further demonstrated another important point that has not been made or evaluated previously: dilute brimonidine makes for a more com-Dilute Brimonidine for LASIK Patients/Pasquali et al fortable patient experience. This is another dimension of the benefi t to this therapy that should be considered when deciding whether to use dilute brimonidine before surgery. 
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